Predictors of QoL ID'd for long-term lymphoma survivors

This article originally appeared here.
Predictors of QoL ID'd for Long-Term Lymphoma Survivors
Predictors of QoL ID'd for Long-Term Lymphoma Survivors

(HealthDay News) -- A considerable proportion of long-term survivors of non-Hodgkin's lymphoma (NHL) have persistently low or worsening quality of life (QoL), which is predicted by age, comorbidity, and the perception of cancer's impact, according to research published online Dec. 3 in the Journal of Clinical Oncology.

Sophia K. Smith, Ph.D., of the Duke Cancer Institute in Durham, N.C., and colleagues surveyed 566 NHL survivors (52 percent women; 87 percent white) at a mean of 15.3 years post-diagnosis, who had participated in a study at 10.4 years post-diagnosis. Changes in QoL were examined, and clinical, demographic, or psychosocial predictors for poor outcomes were assessed.

The researchers found that 32 percent of participants reported persistently high or improved QoL, but 42 percent reported persistently low or worsening QoL. Improvements in physical health were reported by participants who received only biologic systemic therapy. Independent predictors of poor QoL included older age, more comorbidity, and an increasing negative and decreasing positive perception of the impact of cancer. Correlates of a negative perception of cancer's impact included lymphoma symptom burden, less social support, and having received a transplant.

"Moderate to severe symptom burden, limited social support, or having received a [transplant] should alert the clinician to potential need for supportive services," the authors write. "Perceptions of cancer's impact are associated with QoL cross-sectionally and longitudinally; modifying these perceptions may thus provide a strategy for improving QoL."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs